Eli Lilly director Luciano granted $1.2K stock

Eli Lilly director Juan R. Luciano deferred additional board compensation into stock units, increasing his reported equivalent common stock holdings.

Available on EDGAR 09/22/2026 - 04:14 PM EDT Accepted by SEC EDGAR 09/22/2026 - 04:14 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ELI LILLY & Co (LLY) director Juan R. Luciano reported an acquisition of 13.6637 shares of common stock on September 21, 2026, as a grant/award valued at $1,164.89 per share. Under the Lilly Directors' Deferral Plan, these shares are deferred as stock units and will be settled in common stock after his separation from service, bringing his directly held equivalent position to 16,956.8138 shares.

Insider Trade Summary

Grant/Award: 13.6637 shares

Grant/Award 1 txn

Insider LUCIANO JUAN R

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	13.6637	$1,164.89	$16K

Holdings After Transaction: Common Stock — 16,956.8138 shares (Direct)

Holdings Before and After: Common Stock, 16,943.1501 to 16,956.8138 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Key Figures

Shares acquired: 13.6637 shares Per-share value: $1,164.89 per share Holdings after transaction: 16,956.8138 shares +1 more

4 metrics

Shares acquired 13.6637 shares Grant/award acquisition of Eli Lilly common stock on September 21, 2026

Per-share value $1,164.89 per share Value associated with the 13.6637-share grant/award to the director

Holdings after transaction 16,956.8138 shares Total Eli Lilly common stock reported as held directly after the Form 4 transaction

Transaction date September 21, 2026 Date the grant/award acquisition of common stock was effected

Key Terms

Lilly Directors' Deferral Plan, stock units, deferred in lieu of cash compensation, separation from service

4 terms

Lilly Directors' Deferral Plan financial

"as stock units under the Lilly Directors' Deferral Plan and will be settled"

stock units financial

"deferred in lieu of cash compensation as stock units under the Lilly"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

deferred in lieu of cash compensation financial

"the shares acquired pursuant to this filing have been deferred in lieu of cash"

separation from service financial

"will be settled in shares of common stock following the reporting person's separation"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transaction did Eli Lilly (LLY) director Juan R. Luciano report on this Form 4?

He reported a grant/award acquisition of 13.6637 shares of Eli Lilly common stock on September 21, 2026, treated as stock units under the Lilly Directors' Deferral Plan rather than as cash compensation.

Was the Eli Lilly (LLY) Form 4 transaction an open-market purchase or sale?

No. The Form 4 shows a grant/award acquisition of shares in lieu of cash compensation under the Lilly Directors' Deferral Plan, not an open-market buy or sell transaction.

How many Eli Lilly (LLY) shares does Juan R. Luciano report holding after this transaction?

After the September 21, 2026 transaction, Juan R. Luciano reports 16,956.8138 shares of Eli Lilly common stock held directly, including the newly acquired deferred stock units that will be settled in shares upon separation from service.

What price per share is associated with the Eli Lilly (LLY) grant to Juan R. Luciano?

The reported grant/award to Juan R. Luciano is associated with a value of $1,164.89 per share for 13.6637 shares of Eli Lilly common stock, as disclosed in the Form 4 transaction details.

What is the Lilly Directors' Deferral Plan mentioned in the LLY Form 4?

The filing states that, at the reporting person's election, the acquired shares are deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following separation from service.

Was the Eli Lilly (LLY) insider transaction made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates that the Rule 10b5-1 checkbox is not affirmed, and there is no footnote stating that the transaction was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LUCIANO JUAN R

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/21/2026		A		13.6637(1)	A	$1,164.89	16,956.8138	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Christopher Anderson for Juan R. Luciano, pursuant to authorization on file	09/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)